Practical Tips for Managing Nail and Skin Changes While Receiving Talquetamab

Opinion
Video

Panelists discuss how specific talquetamab-related adverse effects such as skin peeling, nail changes, and rashes can be effectively managed through targeted interventions, including topical treatments, protective measures, and preventive strategies tailored to the drug's unique toxicity profile.

Talquetamab-related skin toxicities result from GPRC5D expression in heavily keratinized tissues, particularly affecting palms and soles with characteristic peeling and sloughing. Management strategies focus on aggressive moisturization using emollients such as CeraVe, ammonium lactate 12% cream (AmLactin), and occlusive agents such as Aquaphor applied under cotton gloves overnight. Additional recommendations include topical steroids for inflammation and avoiding hot water exposure that can worsen skin toxicities.

Nail toxicities reflect GPRC5D expression in nail beds, leading to nail fragility, separation, and potential nail loss. Prevention strategies include nail hardeners, vitamin E cuticle oil, and newer products such as Polybalm (comprised of polyphenolic-rich herbal oils with organic waxes). Protective measures involve avoiding trauma through proper footwear, activity modifications, and using finger cots or bandages when nails begin separating to prevent catching them on clothing or hair.

Hygiene maintenance becomes critical during nail and skin toxicities to prevent secondary infections in immunocompromised patients. Recommendations include keeping nails short and clean, wearing gloves during household tasks such as dishwashing, and maintaining good handwashing practices. The comprehensive approach addresses both the active management of existing toxicities and the prevention of complications, recognizing that these effects are generally temporary and resolve over time with continued treatment.

Recent Videos
Two experts are featured in this series.
7 experts are featured in this series.
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
2 experts are featured in this series.
2 experts are featured in this series.
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
Related Content